GSK wins ‘misleading’ advertising case against Reckitt Benckiser’s Nurofen campaign

January 23, 2018 2:00

Pharmaceutical giant Reckitt Benckiser has received another setback in the courts after being found guilty of misleading advertising of Nurofen in a civil case brought by competitor GlaxoSmithKline, the manufacturer of Panadol.

The latest ruling, handed down earlier this month, follows the company being fined $6 million last year for misleading consumers over different pain relief products and being ordered by the Therapeutic Goods Administration to withdraw ad claims about ‘targeted relief’ in 2013.

One of the Nurofen advertisements which caught the eye of GSK

Subscribe to keep reading

Join Mumbrella Pro to access the Mumbrella archive and read our premium analysis of everything under the media and marketing umbrella.

Paul Wallbank

Paul Wallbank was news editor at Mumbrella between June 2017 and June 2019. Previously he's covered business and technology issues for outlets ranging from The Australian and Sydney Morning Herald to the ABC and Business Spectator.

Topics

1 COMMENTS

Chris Gulland 24 Jan 18

I hope they through the book at Reckitt Benckiser, packaging lies are the scourge of all consumers and messing with medication packaging and point of sale, has to be a criminal offence and punished in the harshest way to set an example.

User ID not verified.